다중혈관 관상동맥 환자에서 y-문합을 이용하여 양쪽 내흉동맥만을 사용한 우회술의 조기 성적

Global strategy for asthma management and prevention

世界経済・社会統計 = World development indicators

Prospective Cohort Study

The anterior insular cortex (AIC) is implicated in a wide range of conditions and behaviours, from bowel distension and orgasm, to cigarette craving and maternal love, to decision making and sudden insight. Its function in the re-representation of interoception offers one possible basis for its involvement in all subjective feelings. New findings suggest a fundamental role for the AIC (and the von Economo neurons it contains) in awareness, and thus it needs to be considered as a potential neural correlate of consciousness.

How do you feel--now? The anterior insula and human awareness.

Introduction: The combination of FF, a novel inhaled corticosteroid and VI, a long-acting beta 2 agonist, is under development as a once-daily treatment for asthma and COPD. Objectives: To compare the efficacy of FF/VI with FP/SAL in patients with persistent asthma. Methods: In a randomised, double-blind, double-dummy, parallel-group study, 806 patients received FF/VI (100/25mcg, n=403) or FP/SAL (250/50mcg, n=403) via a new dry powder inhaler, or DISKUS™, respectively. FF/VI was taken once daily in the evening, FP/SAL twice daily. Primary efficacy measure was 0–24h serial weighted mean (wm)FEV 1 after 24 weeks of treatment. Results: Clinically significant improvements from baseline in 0–24h wmFEV 1 were seen with both FF/VI (341mL) and FP/SAL (377mL); the adjusted mean treatment difference was not statistically significant (–37mL, p=0.162). Changes from baseline in 0–4h wmFEV 1 and trough FEV 1 supported the primary findings, as did AQLQ+12, ACT and EQ5-D scores. No difference between treatments in reported exacerbations was found. Both treatments were well tolerated, with no clinically relevant effects on urinary cortisol excretion or vital signs, and no treatment-related serious adverse events; safety profiles were similar across treatment groups. Conclusions: Once-daily FF/VI was as effective as twice-daily FP/SAL in improving lung function in patients with persistent asthma, and no safety issues were identified. No statistically significant treatment difference in efficacy was observed between the two combination treatments. Funded by GSK (HZA113091; NCT01147848).

https://erj.ersjournals.com/content/erj/40/Suppl_56/P1795.full.pdf

Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma

In vitro Studies on the Mechanism of Respiratory Virus-induced Asthma

The beneficial effect of dog exposure is modified by genetic phenotype

Omalizumab pretreatment prevents allergic reactions due to rush immunotherapy (RIT)

Although effective therapies are available to treat asthma and allergic rhinitis, research is now focused on defining the cause of these disorders, including an in-depth analysis of the role of the inflammatory process. An enhanced understanding of the mechanism of the asthmatic inflammatory response should aid in the discovery of more-targeted therapies and preventative

https://www.jacionline.org/article/S0091-6749(98)70236-2/pdf

William W. Busse

Papers

Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma

In vitro Studies on the Mechanism of Respiratory Virus-induced Asthma

The beneficial effect of dog exposure is modified by genetic phenotype

Omalizumab pretreatment prevents allergic reactions due to rush immunotherapy (RIT)

Current research and future needs in allergic rhinitis and asthma